终末期肾病合并严重肢体缺血患者血运重建后的结局与肾功能正常患者的比较
基于德国CRITISCH多中心注册研究,纳入102例终末期肾病(ESRD)和674例非ESRD的严重肢体缺血患者,比较血运重建后2年结局。ESRD患者2年无截肢生存率(35.4% vs 67.2%)、死亡率(55.0% vs 20.7%)和重大截肢率(24.5% vs 15.8%)均显著劣于非ESRD患者。在ESRD组内,不同治疗方式对结局无显著影响;透析患者死亡或重大截肢的风险增加约2倍(HR 2.27),开放手术与EVT相比死亡风险降低(HR 0.58)。作者认为透析患者治疗决策应个体化考虑病变特征,手术和EVT可作为互补选项。
要点
- ESRD合并严重肢体缺血患者2年无截肢生存率仅35.4%,显著低于非ESRD患者的67.2%。
- ESRD组内EVT与旁路手术在死亡、截肢和再干预率上无显著差异。
- 透析患者死亡或重大截肢风险约为非透析患者的2.27倍(HR 2.27,95%CI 1.67-3.10)。
核心结论
- ESRD合并严重肢体缺血患者2年无截肢生存率、总生存率和免于重大截肢率均低于非ESRD患者。
- 心血管合并症对结局参数无显著影响,ESRD组内治疗方式选择不影响无截肢生存率。
- 作者认为透析患者的治疗决策应特别考虑个体病变特征和血管疾病,手术血运重建和EVT可作为互补选项。
研究设计与样本
- 基于德国CRITISCH多中心注册研究的询问性数据收集,纳入102例ESRD和674例非ESRD的严重肢体缺血患者。
- 分析四种治疗方式:旁路手术、血管内治疗(EVT)、股动脉内膜剥脱术和无血管干预(保守治疗或初期重大截肢)。
- 预设终点为无截肢生存率(AFS)、死亡、重大截肢和再干预,采用Cox回归模型分析独立危险因素。
主要发现
- 2年AFS:ESRD组35.4% vs 非ESRD组67.2%(P < .001)。
- 2年死亡率:ESRD组55.0% vs 非ESRD组20.7%(P < .001);重大截肢率:ESRD组24.5% vs 非ESRD组15.8%(P = .029)。
- ESRD组内EVT vs 旁路手术:死亡或重大截肢56.9% vs 76.9%(P = .225);死亡46.2% vs 61.5%(P = .372);截肢15.4% vs 15.4%(P = 1.000);再干预32.3% vs 15.4%(P = .324)。
- Cox回归:透析患者死亡或重大截肢的风险比HR 2.27(95%CI 1.67-3.10,P < .001);开放手术治疗(全部患者合并)与EVT相比死亡风险HR 0.58(95%CI 0.37-0.91,P = .017)。
- 合并症对AFS、生存率、再干预或重大截肢未见明显影响。
临床怎么用
- 作者认为透析患者的治疗决策应特别考虑个体病变特征和血管疾病。
- 作者认为手术血运重建和EVT可作为互补选项。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An analysis was conducted of intermediate outcomes and possible influencing factors in patients with end-stage renal disease (ESRD) and critical limb ischemia after lower limb revascularization compared with patients with regular renal function (non-ESRD). METHODS: Data collection was performed by inquiry of the German multicenter registry of First-Line Treatments in Patients with Critical Limb Ischemia (CRITISCH); 102 ESRD patients and 674 non-ESRD patients were included. Four different therapy modalities were analysed: bypass surgery, endovascular therapy (EVT), femoral artery endarterectomy, and no vascular intervention (conservative treatment or primary major amputation). Predefined end points were amputation-free survival (AFS), death, major amputation, and reintervention. Cox regression models were built to analyze independent risk factors for outcome parameters. RESULTS: ESRD patients showed inferior results at 2 years in the rate of AFS (ESRD, 35.4%; non-ESRD, 67.2%; P < .001). Similarly, death rate (ESRD, 55.0%; non-ESRD, 20.7%; P < .001) and major amputation rate (ESRD, 24.5%; non-ESRD, 15.8%; P = .029) were significantly elevated for ESRD patients. The choice of therapeutic approach in ESRD did not influence the incidence of the investigated end points (death or major amputation: EVT, 56.9% vs bypass, 76.9% [P = .225]; death: EVT, 46.2% vs bypass, 61.5% [P = .372]; amputation: EVT, 15.4% vs bypass, 15.4% [P = 1.000]; reintervention: EVT, 32.3% vs bypass, 15.4% [P = .324]). Cox regression analysis indicated that dialysis patients carry a twofold increased hazard of death or major amputation (hazard ratio, 2.27; 95% confidence interval, 1.67-3.10; P < .001), and open surgical treatment (all patients combined) was associated with reduced risk of death compared with EVT (hazard ratio, 0.58; 95% confidence interval, 0.37-0.91; P = .017). Comorbidities were not found to have a noticeable impact on AFS, survival, reintervention, or major amputation. CONCLUSIONS: Two-year AFS, overall survival, and freedom from major amputation were decreased in ESRD patients compared with non-ESRD patients with critical limb ischemia. Cardiovascular comorbidities were without significant impact on outcome parameters, whereas choice of treatment modality within the ESRD group did not influence AFS. Decision-making in ESRD as to choice of therapeutic approach in dialysis patients should notably account for the individual's lesion characteristics and vascular disease; surgical revascularization and EVT may be used as complementary options.
引用
- Meyer A, Fiessler C, Stavroulakis K, et al. Outcomes of dialysis patients with critical limb ischemia after revascularization compared with patients with normal renal function. J Vasc Surg. 2018. PMID: 29598891. doi:10.1016/j.jvs.2017.12.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。